En Es
Categories

Industry News

Una tecnología para la detección del cáncer basada en la IA recibe aprobación de la FDA

By Medimaging en español staff writers
02 Jan 2019

Imagen: ProFound AI es una solución de flujo de trabajo y detección de cáncer mediante aprendizaje profundo para la DBT (Fotografía cortesía de iCAD).Una solución nueva de software para la detección de cáncer que usa aprendizaje profundo para la tomosíntesis digital de seno (DBT, por sus siglas en inglés) ha recibido la aprobación de la FDA de los EUA para ventas comerciales y uso clínico en los EUA. La solución denominada ProFound AI se basa en inteligencia artificial (IA) y ha sido desarrollada por iCAD, Inc. (Nashua, NH, EUA), un proveedor de soluciones de terapia y detección para el cáncer.

ProFound AI es una solución de flujo de trabajo y detección de cáncer, de aprendizaje profundo para la DBT, que brinda beneficios críticos para los radiólogos, sus instalaciones y sus pacientes a través de una mejora en las tasas de detección del cáncer en un promedio del 8% y una reducción en las tasas innecesarias de llamar nuevamente a los pacientes en un promedio del 7%. La tecnología está entrenada para detectar densidades de tejidos blandos malignos y calcificaciones. También proporciona a los radiólogos información de puntuación que representa la probabilidad de que una detección o un caso sea maligno según el gran conjunto de datos de imágenes clínicas utilizadas para entrenar el algoritmo.

ProFound AI ha recibido la aprobación de la FDA en base a los resultados clínicos positivos de un gran estudio de lectores realizado a principios de este año y presentado en el congreso anual de la Sociedad Radiológica de América del Norte (RSNA) en Chicago, EUA. En el estudio, 24 radiólogos leyeron 260 casos de tomosíntesis, con y sin la solución ProFound AI. Los hallazgos del estudio revelaron mayores tasas de detección de cáncer, reducción de falsos positivos y necesidad de llamar nuevamente a los pacientes, y una disminución significativa de más del 50% en el promedio en los tiempos de interpretación.

“La obtención de la aprobación de la FDA para ProFound AI abre un mercado nuevo y sustancial direccionable para iCAD. Esto nos permite ofrecer a los médicos de todo el mundo una solución de flujo de trabajo y detección de cáncer sin rival basada en los últimos avances en aprendizaje profundo”, dijo Stacey Stevens, vicepresidenta ejecutiva y directora estratégica y comercial de iCAD. “Los resultados del estudio clínico de los lectores y las pruebas independientes completas han mostrado mejoras sin precedentes tanto en el desempeño clínico como en la eficiencia de la lectura. Estamos orgullosos de presentar una tecnología revolucionaria que transformará fundamentalmente la detección de cáncer de mama y la atención a los pacientes”.

Enlace relacionado:
iCAD, Inc.



E-mail Print
FaceBook Twitter Google+ Linked in

iCAD

Offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers
More info

More articles about iCAD

18 Sep 2019
AI Solution Supporting Wins Best New Radiology Solution Award
An FDA-cleared artificial intelligence (AI) solution that supports breast cancer detection in 3D tomosynthesis has been selected as the winner of “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program.
Read More
25 Dec 2018
Cancer Detection Technology Built on AI Receives FDA Clearance
A new deep-learning cancer detection software solution for digital breast tomosynthesis (DBT) has received clearance from the US FDA for commercial sales and clinical use in US. The solution named ProFound AI is built on artificial intelligence (AI) and has been developed by iCAD, Inc, a provider of cancer detection and therapy solutions.
Read More
25 Oct 2018
Study Demonstrates Advantages of AI for Digital Breast Tomosynthesis
A study of digital breast tomosynthesis (DBT) cancer detection software by iCAD, Inc. has demonstrated unprecedented improvements in clinical performance and reading times, validating the substantial benefits of Artificial Intelligence (AI) when used with three-dimensional (3D) mammography.
Read More

Additional news

23 Jun 2020
Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience
Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online.
Read More
12 Jun 2020
Global Magnetic Resonance Imaging (MRI) Market to be driven by Advancements in Medical Diagnostics
The global magnetic resonance imaging (MRI) market was valued at USD 5.90 billion in 2017 and is projected to register a CAGR of 5.2% from 2018 to 2026, driven by increased demand for MRI equipment across the world due to a substantial rise in incidence of disorders related to spine, neurology, orthopedic, cardiovascular, head and neck, and abdominal and prostate.
Read More
30 May 2020
MEDICAL FAIR ASIA 2020 Set to Take Place in Singapore from 9-11 December 2020
MEDICAL FAIR ASIA 2020 is set to take place in Singapore from 9-11 December 2020 at Marina Bay Sands, with the exhibition featuring the latest medical technology and innovations, and healthcare equipment and supplies.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
17 Apr 2020
ECR 2020 to Go Ahead as Online Congress on July 15-19, 2020
In view of the ongoing spread of COVID-19 across the world and its growing global impact, the board of directors of the European Society of Radiology (Vienna) has decided not to hold an onsite European Congress of Radiology (ECR) in 2020. Instead, ECR 2020 will go ahead as an online congress to ensure a safe experience for its members, partners, staff and the general public.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
01 Apr 2020
SymphonyAI Acquires TeraRecon
SymphonyAI Group (Los Altos, CA, USA), an operating group of leading business-to-business artificial intelligence (AI) companies, has acquired TeraRecon (Durham, NC, USA), an advanced visualization and AI solution provider for medical imaging.
Read More
23 Mar 2020
Artificial Intelligence-Based Methods to Cut MRI Read Times Receives USD 250K Grant
 Research to detect and predict blocked arteries and cardiovascular risk using knee MRI images conducted by Chun Yuan, Ph.D., Professor of Radiology and Bioengineering and Vice Chair for Global Affairs at the University of Washington (Seattle, WA, USA) has been recognized and awarded a grant by the American Heart Association’s (AHA) Institute for Precision Cardiovascular Medicine (Dallas, TX, USA).
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions